Graph Therapeutics brings total funding to over $10M to advance precision immunology

2026-06-22 · Source: Tech.eu - Tech.eu · Field: Health & Wellbeing — Pharmaceuticals & Biotechnology, Medical Devices & Health Technology · Depth: Fundamental Awareness, quick

Summary

Graph Therapeutics, a biotech company focused on precision medicines for inflammatory and immune-mediated diseases, has secured a new \$5 million investment led by Daphni, bringing its total funding to over \$10 million. This capital, which includes non-dilutive grants from the Austrian Research Promotion Agency (FFG) and Austria Wirtschaftsservice (AWS, alongside existing investors SquareOne, Merantix Capital, and NAVEC Investment Management), will advance Graph's internal drug discovery pipeline across multiple disease indications. The company utilizes a proprietary "lab-in-the-loop" AI platform that integrates perturbation modelling of live patient samples, functional and multi-omics profiling, and advanced machine learning. This platform decodes immune dysfunction at scale by generating insights directly from real patient tissue, identifying disease mechanisms, novel therapeutic targets, and biomarkers to inform differentiated therapies. The platform is substantially validated and de-risked, creating opportunities for strategic partnerships.

Key takeaway

For investors evaluating biotech ventures in precision immunology, Graph Therapeutics' successful over \$10 million funding round and validated "lab-in-the-loop" AI platform signal a de-risked approach to drug discovery. Your due diligence should prioritize companies demonstrating robust integration of AI with multi-omics and live patient data. This model, proven through clinically relevant biological models, suggests a strong foundation for identifying novel therapeutic targets and securing strategic partnerships.

Key insights

AI-powered analysis of live patient cells, multi-omics data, and functional biology decodes immune dysfunction for precision immunology.

Principles

• "Lab-in-the-loop" AI platforms integrate real-world biological data.
• Perturbation modelling combined with multi-omics reveals disease mechanisms.
• Direct patient tissue insights inform novel therapeutic target identification.

Method

The "lab-in-the-loop" AI platform combines perturbation modelling of live patient samples, functional and multi-omics profiling, and advanced machine learning to decode immune dysfunction at scale.

In practice

• Apply AI to multi-omics and live patient data for disease mechanism discovery.
• Validate therapeutic platforms using clinically relevant biological models.
• Seek strategic partnerships for platform out-licensing and broader impact.

Topics

• Precision Immunology
• AI Drug Discovery
• Multi-omics
• Biotech Funding
• Inflammatory Diseases
• Lab-in-the-loop AI

Best for: Investor, Entrepreneur, Director of AI/ML

Related on AIssential

• Is AI Drug Discovery Becoming a Data Infrastructure Race? — AI drug discovery's primary bottleneck is the availability of diverse, relevant biological training data, not model architecture or compute.
• Cricketer Pat Cummins backs longevity startup Everlab’s $65 million Series A - Startup Daily — AI-enhanced preventative healthcare leverages biomarker diagnostics to detect early health issues and coordinate personalized care.
• Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation — MIDAS, a multimodal GNN, effectively identifies novel immuno-oncology targets by integrating diverse biological data.
• Exclusive: Fathom raises $47M, blending AI and physics in drug discovery - Endpoints News — Fathom Therapeutics combines AI and physics-based simulations to accelerate drug discovery.
• SPOKE: A massive biomedical knowledge graph for precision health and drug discovery — SPOKE integrates vast biomedical data into a knowledge graph for drug discovery and precision medicine.
• Triomics Raises $22M to Scale Oncology AI for Early Cancer Detection and Treatment — Oncology AI firm Triomics raised \$22M to scale its technology for early cancer detection and treatment.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Tech.eu - Tech.eu.